恩替卡韦联合介入疗法用于HBV DNA阴性乙肝肝癌的疗效观察

摘要

目的：观察恩替卡韦联合介入疗法用于乙型肝炎（以下简称“乙肝”）病毒（HBV）DNA阴性乙肝肝癌的临床疗效。方法：选取HBV DNA阴性乙肝肝癌患者100例，按随机数字表法分为观察组和对照组，各50例。对照组患者接受介入治疗，经股动脉入路穿刺，将注射用盐酸吡柔比星+超液化碘油注入载瘤动脉，至载瘤动脉血流停滞，同时进行常规保肝治疗；观察组患者在对照组基础上加服恩替卡韦片1 mg，qd，持续治疗6个月。比较两组患者的临床疗效、HBV DNA定量、Child-Pugh评分和肝功能指标。结果：观察组患者总缓解率为44.0％，显著高于对照组的26.0％，差异有统计学意义（P＜0.05）。两组患者治疗前的HBV DNA定量、Child-Pugh评分及肝功能指标比较，差异均无统计学意义（P＞0.05）；治疗后，观察组患者的HBV DNA定量、Child-Pugh评分、甲胎蛋白、丙氨酸转氨酶、总胆红素及天冬氨酸转氨酶均明显降低，与对照组比较差异均有统计学意义（P＜0.05）。结论：恩替卡韦联合介入疗法能明显提高HBV DNA阴性乙肝肝癌临床疗效，改善患者肝功能指标。%OBJECTIVE:To observe the clinical efficacy of entecavir combined with intervention in the treatment of liver cancer patients with HBV DNA-negative hepatitis B. METHODS:100 liver cancer patients with HBV DNA-negative hepatitis B were random-ly divided into observation group and control group,50 cases in each group. Control group received intervention,percutaneous punc-ture of femoral artery,then injected Pirarubicin hydrochloride for injection + lipiodol in parent artery until blood stagnation,and also conventional liver protection therapy was conducted;observation group additionally received 1 mg Entecavir tablet,qd,for continuous 6 months. Clinical efficacy,HBV DNA quantification,Child-Pugh score and liver function indexes in 2 groups were compared. RE-SULTS:The total effective rate in observation group was 44.0%,which was significantly higher than control group(26.0%),the dif-ference was statistically significant(P<0.05). There were no significant differences in HBV DNA quantification,Child-Pugh score and liver function indexes between 2 groups(P>0.05). After treatment,HBV DNA quantification,Child-Pugh score,fetoprotein,alanine aminotransferase, total bilirubin and aspartate aminotransferase significantly decreased in observation group,the differences were statis-tically significant compared with control group (P<0.05). CONCLUSIONS:Entecavir combined with intervention can obviously im-prove the clinical efficacy and liver function indexes of liver cancer patients with HBV DNA-negative hepatitis B.